echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Green leaf Pharmaceutical Co., Ltd. has invested nearly 1.447 billion yuan to acquire Boan bio

    Green leaf Pharmaceutical Co., Ltd. has invested nearly 1.447 billion yuan to acquire Boan bio

    • Last Update: 2019-12-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On December 1, green leaf pharmaceutical released a corporate announcement, announcing to purchase 98% equity of Shandong Boan Biotechnology Co., Ltd (Boan bio) with RMB 1446.7 million, in order to accelerate the global layout of bio pharmaceutical business Bio medicine market! Sullivan research shows that during the past 2014-2018 period, the global market of biological agents has grown from US $194.4 billion to US $261.8 billion, with a compound annual growth rate of 7.7% From 2018 to 2023, the market will grow at a compound annual growth rate of 9.0%, and the sales revenue will reach US $402.1 billion in 2023 Compared with the global market, China's biological preparation market has a broader development prospect According to Sullivan research, the sales revenue of China's biological preparation market increased from RMB 116.7 billion in 2014 to RMB 262.2 billion in 2018, with a compound annual growth rate of 22.4% It is expected that the sales revenue of China's biological preparation market will further increase at a compound annual growth rate of 19.6% from 2018 to 2023, reaching RMB 641.2 billion Driven by the huge unmet demand, growing R & D investment, major development of biotechnology and favorable policies, the market of Biopharmaceutics will continue to grow in the future It's hard to bite into the bio medicine market, and M & A helps The biological medicine market has very high barriers to entry, mainly including intensive integration of knowledge and skills, 8-10 years of complex development process, difficult to replicate in technology, challenging production and supply chain management, huge capital investment and strict supervision, which put forward higher requirements for pharmaceutical enterprises entering this field The addition of Boan bio can help green leaf pharmaceutical to enter and stabilize the bio pharmaceutical business On the one hand, Boan bio will greatly enrich the bio pharmaceutical project reserve of LVYE pharmaceutical Boan bio has a strong product line under development covering different stages of research and development, including a comprehensive product line of similar biological drugs (due to its excellent target and mechanism of action, relatively low clinical risk) and innovative drugs (with the potential to become the first new drug and / or the best drug of the same kind in the same product and / or indication category) Products under research: biological similar drugs under research: on the other hand, Boan biology has accumulated rich experience in antibody generation and lead compounds, cell line establishment and process development, pilot production and commercial production With the addition of Boan bio, LVYE pharmaceutical can realize the comprehensive upgrade of bio pharmaceutical software and hardware in a short period of time It can not only continue to involve in clinical development, but also take into account commercial production With the global sales network of LVYE pharmaceutical, this acquisition will accelerate the company's performance growth, further enhance the core competitiveness of its global product line, and finally become a leading country in the world The international innovation pharmaceutical company is of great strategic significance The determination of various pharmaceutical companies to enter the biomedical market by the end of 2018, Baiji Shenzhou spent $430 million to acquire two dual antibacterials and technology platforms of zymeworks; on May 29, 2019, hausen pharmaceutical spent $220 million to enter into the development and commercialization cooperation of CD19 monoclonal antibody with viela bio in China; a week ago, Novartis purchased the medicines company with $9.7 billion Biopharmaceutics will always be the focus of attention in the industry, especially with the continuous deepening of people's understanding of disease science and the continuous progress of biotechnology, biopharmaceutics will be the strategic commanding point of the drug market, which is a very attractive opportunity for any pharmaceutical enterprise Mengmeng's article is the integrated content of yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.